Coronavirus LIVE Updates: A new coronavirus variant is on the rise in New York City, researchers said on Wednesday. The new variant, known as B.1.526, was first identified in samples collected in New York in November, and by mid-February represented about 12% of cases, researchers at Columbia University Vagelos College of Physicians and Surgeons, said on Wednesday. The variant was also described in research published online this week by the California Institute of Technology. Neither study has been reviewed by outside experts. It shares some similarities with a more transmissible and intractable variant discovered in South Africa.
The Columbia researchers said an analysis of publicly available databases did not show a high prevalence of coronavirus variants recently identified in South Africa and Brazil in case samples from New York City and surrounding areas. “Instead we found high numbers of this home-grown lineage,” Dr. Anne-Catrin Uhlemann, assistant professor in the division of infectious diseases at Columbia University’s College of Physicians and Surgeons, said in a statement.
Meanwhile, China is moving ahead with two more Covid vaccines in the regulatory process, one from state-owned company Sinopharm and another from a private company CanSino, AP reports. Both vaccines have submitted been to regulators for approval this week. CanSino said that Chinese regulators are reviewing its application for its Covid vaccine, in a stock filing on Wednesday. Sinopharm’s subsidiary the Wuhan Institute of Biological Products announced Wednesday that it had submitted an application Sunday and that regulators were reviewing it.
China already has approved two vaccines that it has been using in a mass immunization campaign. One of them is also from Sinopharm, but it was developed by its Beijing subsidiary. The other is the Sinovac vaccine. The Wuhan shot from Sinopharm is 72.51% effective, the company said. Both shots from Sinopharm rely on inactivated viruses, a traditional technology.
CanSino’s vaccine is a one-dose shot that relies on a harmless common cold virus, called an adenovirus, to deliver the spike gene of the virus into the body. The technology is similar to both Astrazeneca and Johnson & Johnson’s vaccines, which rely on different adenoviruses. CanSino’s vaccine is 65.28% effective, the company said Wednesday. Neither company has published its trial data in peer-reviewed scientific journals yet.
The Columbia study found that B.1.526 shares some worrying characteristics with B.1.351, the variant first identified in South Africa, and P.1., which was first identified in Brazil. Several studies have suggested that those new variants are more resistant to some existing vaccines than earlier versions of the coronavirus. The researchers said the main concern is a change in one area of the virus’ spike protein, called E484K, that is present in all three variants. The E484K mutation is believed to weaken the body’s immune response to the virus.
Studies have shown that recently launched coronavirus vaccines are still likely to neutralise the virus and protect against severe illness, even for infections with new variants. Vaccine makers are also working to develop booster shots to combat mutated versions of the virus.